LCM
KNSA icon

Laurion Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Laurion Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,170
Closed -$364K – 347
2025
Q2 		$364K Buy
+13,170
New +$335K 0.01% 282
2018
Q4 		– Sell
-111,111
Closed -$2.83M – 1263
2018
Q3 		$2.83M Hold
111,111
– – 0.03% 475
2018
Q2 		$1.93M Buy
+111,111
New +$2.01M 0.02% 615

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Laurion Capital Management's KNSA Position: Q3 2025 in Review

Laurion Capital Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2025, closing a stake of 13,170 shares — an estimated $364K sold.

Laurion Capital Management first reported a position in KNSA in Q2 2018 and held it in 3 quarters. The position peaked at $2.83M in Q3 2018. 204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

  • Laurion Capital Management reported no remaining Kiniksa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Laurion Capital Management sold 13,170 Kiniksa Pharmaceuticals shares in Q3 2025, an estimated $364K.
  • Laurion Capital Management first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Laurion Capital Management's Kiniksa Pharmaceuticals position peaked at $2.83M in Q3 2018.
  • 204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on Laurion Capital Management's 13F filing for Q3 2025, filed 17 Nov 2025.